Quantcast
Last updated on April 16, 2014 at 6:17 EDT

Latest Pitavastatin Stories

2014-04-02 08:26:30

First and Goal Campaign encourages small, achievable accomplishments in cholesterol management NEW YORK, April 2, 2014 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. today announced a partnership with Kurt Warner, Super Bowl winner and two-time NFL MVP, and his wife Brenda, to launch First and Goal, a national education initiative to help people prioritize heart health. The campaign encourages the 71 million Americans living with high cholesterol to develop a personalized game plan to get...

2013-06-17 12:28:59

Study results presented at ENDO 2013 Annual Meeting SAN FRANCISCO, June 17, 2013 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE: LLY) announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO(®) (pitavastatin) 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin...

2013-03-07 08:28:05

Study results presented as late-breaker at CROI 2013 this week ATLANTA, March 7, 2013 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company (NYSE:LLY) announced results of a study evaluating the efficacy of LIVALO(®) (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C) in HIV-infected adults with high cholesterol, or dyslipidemia. The study was designed as a superiority trial for the primary endpoint,...

2012-07-22 10:21:11

WASHINGTON, July 22, 2012 /PRNewswire/ -- Kowa Pharmaceuticals America, Inc. (Kowa Pharmaceuticals) and Eli Lilly and Company (Lilly) (NYSE: LLY) today released results from a pharmacokinetic (PK) study exploring potential drug interaction between the cholesterol medication pitavastatin (LIVALO) 4 mg and the protease inhibitor (PI) combination darunavir/ritonavir (Prezista(®)/Norvir(®)) 800mg/100mg in healthy volunteers.(1) The study, presented at the 19(th) International AIDS...

Diabetes, Memory Loss Warnings Added to Cholesterol Medications
2012-02-29 06:16:38

The U.S. Food and Drug Administration (FDA) announced on Tuesday that they would be adding memory loss and diabetes warnings to the labels of cholesterol-lowering drugs known as statins. According to Reuters reporters Bill Berkrot and Ransdell Pierson, the label changes come after the agency learned of studies in which taking statins could lead to a small increased risk of cognitive issues such as memory loss or confusion, as well as a slight spike in blood sugar levels and the risk of...

2010-06-21 07:00:00

MONTGOMERY, Ala. and INDIANAPOLIS, June 21 /PRNewswire-FirstCall/ -- Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed...

2010-03-24 16:57:00

SILVER SPRING, Md., March 24 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved the use of Xifaxan for reduction in the risk of the recurrence of overt hepatic encephalopathy (HE) in patients with advanced liver disease. This is a new use for Xifaxan (rifaximin), a drug that has been approved for the treatment of traveler's diarrhea. (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) Hepatic encephalopathy is a worsening of brain function that can...

2009-12-23 09:52:00

INDIANAPOLIS and MONTGOMERY, Ala., Dec. 23 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY), Kowa Company, Limited, and Kowa's U.S. subsidiary, Kowa Pharmaceuticals America, Inc., today announced that Lilly and Kowa Pharmaceuticals America have entered into a co-promotion agreement in the United States to commercialize LIVALO® (pitavastatin). Lilly and Kowa have also entered into a licensing agreement in Latin America. LIVALO is a statin approved by the U.S....

2009-09-02 06:09:00

BARCELONA, Spain, Sept. 2 /PRNewswire/ -- LIVALO (pitavastatin) may have the potential for fewer drug-drug interactions, versus other statins, as evidenced by a new study that evaluated the effects of itraconazole, an antifungal medication, on the pharmacokinetics of LIVALO in healthy volunteers. The data were presented by Kowa at the European Society of Cardiology (ESC) Congress in Barcelona, Spain. Many statins currently prescribed in the United States, such as atorvastatin and...

2009-08-03 16:23:00

MONTGOMERY, Ala. and RALEIGH, N.C., Aug. 3 /PRNewswire/ -- Kowa Research Institute (KRI) based in Raleigh, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug Administration (FDA) has approved LIVALO(R) (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia. "The approval of LIVALO...